The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An overview of CAR T-cell therapies in the treatment of patients with MCL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses the use of CAR-T therapy for patients with mantle cell lymphoma (MCL). There is a clear unmet need for patients with MCL who have failed treatment with BTK inhibitors. Two CAR T-cell therapies have recently been approved in MCL: brexucabtagene autoleucel (brexu-cel) based on the results of the ZUMA-2 study (NCT02601313) and lisocabtagene maraleucel (liso-cel) based on the TRANSCEND study (NCT02631044). Whilst there are barriers to the administration of CAR-T therapies, these approvals are promising for patients with relapsed/refractory (R/R) MCL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AstraZeneca, Pharmacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, BeiGene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics; Research funding: Roche/Genentech, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics.
